# Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

> **NCT05389046** · NA · UNKNOWN · sponsor: **Peking University** · enrollment: 252 (estimated)

## Conditions studied

- Outpatients / Inpatients With Depression

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Escitalopram+Aripiprazole
- **DRUG:** Escitalopram+omega-3 PUFAs
- **DRUG:** Escitalopram+Aripiprazole+omega-3 PUFAs

## Key facts

- **NCT ID:** NCT05389046
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-15
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389046, "Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05389046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*